LACTIC ACID BACTERIA AND BIFIDOBACTERIA FOR TREATING ENDOTOXEMIA

• US 20160113976A1
• Filed: 12/30/2015
• Published: 04/28/2016
• Est. Priority Date: 07/30/2009
• Status: Active Grant

• Current Assignee: International N&H Denmark APS (International Flavors & Fragrances Incorporated)
• Original Assignee: DuPont Nutrition Biosciences ApS (International Flavors & Fragrances Incorporated)
• Inventors: BURCELIN, REMY, CARCANO, DIDIER, DESREUMAUX, PIERRE, LAHTINEN, SAMPO, RAUTONEN, NINA, PUTAALA, HELI, TIIHONEN, KIRSTI, BARRANGOU, RODOLPHE
• Granted Patent: US 10,543,239 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2035/115 Probiotics
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/74 Bacteria therapeutic use of a bacterial protein A61K38/00
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.

Claims

1-44. -44. (canceled)

45. A method of inhibiting bacterial translocation in a mammal in need thereof, the method comprising administering an effective amount of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof.

46. A method according to claim 45, for inhibiting the translocation of bacteria to the liver and/or spleen.

47. A method according to claim 45, for inhibiting the translocation of bacteria into tissue selected from mesenteric adipose tissue, subcutaneous adipose tissue, mesenteric ganglion and/or subcutaneous ganglion.

48. A method according to claim 45, for inhibiting the translocation of bacteria selected from the family Enterobacteriaceae or the class Bacteroidetes.

61. A method according to claim 46 for inhibiting the translocation of bacteria selected from the family Enterobacteriaceae or the class Bacteroidetes.

62. A method according to claim 47 for inhibiting the translocation of bacteria selected from the family Enterobacteriaceae or the class Bacteroidetes.

63. A method according to claim 45, wherein the bacterium is a probiotic lactic acid bacterium and/or a probiotic Bifidobacterium.

64. A method according to claim 45, wherein the bacterium is a bacterium selected from the genera Lactobacillus or Bifidobacterium and mixtures thereof.

65. A method according to claim 64, wherein the bacterium is selected from the species Lactobacillus acidophilus, Lactobacillus plantarum, Bifidobacterium animalis, Bifidobacterium lactis, or Bifidobacterium bifidium, and mixtures thereof.

66. A method according to claim 65, wherein the bacterium is Lactobacillus acidophilus strain NCFM, Bifidobacterium animalis subsp. lactis strain 420, Lactobacillus salivarius strain 33, or a mixture thereof.

67. A method according to claim 45, wherein the bacterium is administered in combination with one or more prebiotics.

68. A method according to claim 67, wherein the prebiotic is selected from alginate, xanthan, pectin, locust bean gum, inulin, guar gum, a galacto-oligosaccharide, a fructo-oligosaccharide, polydextrose, lactitol, lactosucrose, a soybean oligosaccharide, palatinose, an isomalto-oligosaccharide, a gluco-oligosaccharide or a xylo-oligosaccharide, or a mixture of any thereof.

69. A method according to claim 68, wherein the prebiotic is polydextrose.

49-60. -60. (canceled)